Increased Uptake of HPV Vaccine Projected to Reduce Oropharyngeal Cancer Incidence Over 25 Years
A new study projects that increasing HPV vaccination rates will trend toward reduced incidence of oropharyngeal cancer among younger adults until 2045.
A new study projects that increasing HPV vaccination rates will trend toward reduced incidence of oropharyngeal cancer among younger adults until 2045.
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
In this study, researchers sought to determine if use of a tumor specific vaccine would improve the efficacy of PD-1 immune checkpoint inhibition in patients with incurable HPV-16 cancer.
Updated vaccine designed to prevent cancers and disease caused by nine HPV types.
Proportion of teens up to date with HPV vaccines also increasing, researchers found.
Canadian investigators conducted a national observational study in which women and girls living with HIV underwent HPV vaccination.
High-certainty evidence for cervical cancer protection in adolescent girls and young women aged 15 to 26 years.
A retrospective study demonstrates an increase in HPV16-positive status among patients with OPSCC and a corresponding increase in age at diagnosis.
Using a data sample from the CDC National Program for Cancer Registries, investigators determined how demographic factors — age, race, and sex — impact 5-year survival rates for HPV-associated cancers from initial diagnosis until death.
This fact sheet examines possible links between human papillomaviruses (HPVs) and cancer.